Oncol Case Rep J | Volume 3, Issue 3 | Case Report | Open Access

Combination of Loco-Regional Chemotherapy and Oncolytic Virotherapy to Treat a Metastatic Gastro-Esophageal Tumor

Benjamin Gesundheit1*, Jayadeepa Srinivas Raju1, Yehudit Posen1, Ronald Ellis1, Karl Aigner2 and Arno Thaller3

1Rapo Yerape Ltd., Jerusalem, Israel
2Medias Klinik, Burghausen, Germany
3Practice Clinic for General Medicine, Markt Berolzheim, Germany

*Correspondance to: Benjamin Gesundheit 

Fulltext PDF

Abstract

A palliative patient with a refractory end-stage metastatic gastroesophageal tumor did not respond to conventional chemotherapy, lost the ability to swallow, and was considered palliative. She then was treated with Locoregional Chemotherapy (LRC), followed by oncolytic virus immunotherapy with intratumor injection of three Oncolytic Viruses (OV). The extent, size and number of metastases became much reduced, tumor biomarkers improved, and she regained the ability to swallow. Due to her switching to another medical center that did not have ethical approval, she could not continue immunotherapy and expired. These initial encouraging results suggest that a combination of LRC and OV immunotherapy might be an attractive treatment modality for some refractory tumors.

Keywords:

Gastric tumor; Oncolytic virotherapy; Immunotherapy; Loco-regional chemotherapy

Citation:

Gesundheit B, Srinivas Raju J, Posen Y, Ellis R, Aigner K, Thaller A. Combination of Loco-Regional Chemotherapy and Oncolytic Virotherapy to Treat a Metastatic Gastro-Esophageal Tumor. Oncol Case Report J. 2020;3(3):1029..

Subscribe to Our Newsletter